

IN THE CLAIMS:

Please cancel claims 3 and 4.

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims

Claims 1-4. (Canceled)

5. (Currently Amended) A The composition of claim 4 for alleviating neuropathic pain, comprising:

a prosaposin receptor agonist consisting of the sequence shown in SEQ ID NO:2 in a neuropathic pain alleviating effective amount; and

a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is in a controlled release formulation.

6. (Currently Amended) A The composition of claim 4 for alleviating neuropathic pain, comprising:

a prosaposin receptor agonist consisting of the sequence shown in SEQ ID NO:2 in a neuropathic pain alleviating effective amount; and

a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is in a liposomal form.

7. (Currently Amended) A The composition of ~~claim 4~~ for alleviating neuropathic pain, comprising:

a prosaposin receptor agonist consisting of the sequence shown in SEQ ID NO:2 in a neuropathic pain alleviating effective amount; and

a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is in a lyophilized form.

8. (Currently Amended) A The composition of ~~claim 4~~ for alleviating neuropathic pain, comprising:

a prosaposin receptor agonist consisting of the sequence shown in SEQ ID NO:2 in a neuropathic pain alleviating effective amount; and

a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is in a unit dosage form.

Claims 9-31. (Canceled)

32. (Currently Amended) The composition of any of claims 5-8 ~~claim 4~~, wherein the neuropathic pain results from diabetes.